Vanda Pharmaceuticals (VNDA) Return on Capital Employed (2011 - 2026)

Vanda Pharmaceuticals has disclosed Return on Capital Employed across 16 years of filings, most recently posting 49.24% for Q1 2026.

• Return on Capital Employed for Q1 2026 came in at 49.24%, down 3583.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 49.24% (down 3583.0% YoY), and the FY2025 annual result was 35.37%, down 2801.0% from the prior year.
• Return on Capital Employed came in at 49.24% for Q1 2026 at Vanda Pharmaceuticals, down from 37.8% in the prior quarter.
• In the past five years, Return on Capital Employed ranged from a high of 4.76% in Q1 2022 to a low of 49.24% in Q1 2026.
• The 5-year median for Return on Capital Employed is 4.52% (2024), against an average of 9.21%.
• Across the five-year window, Return on Capital Employed plunged 120 bps in 2023 and sank 3583 bps in 2026, its largest moves.
• Vanda Pharmaceuticals' Return on Capital Employed stood at 1.18% in 2022, then plunged by 312 bps to 2.5% in 2023, then plunged by 195 bps to 7.38% in 2024, then slumped by 412 bps to 37.8% in 2025, then slumped by 30 bps to 49.24% in 2026.
• The last three Return on Capital Employed figures came in at 49.24% (Q1 2026), 37.8% (Q4 2025), and 24.46% (Q3 2025), per Business Quant data.